Targeting the programmed cell death-1 pathway in rheumatoid arthritis

Autoimmunity Reviews

Volumn 16, Issue 8, 2017, Pages 767-773

  Sandigursky, Sabina ^a   Silverman, Gregg J ^a   Mor, Adam ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Lymphocytes; Programmed cell death 1; Rheumatoid arthritis; Signaling

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PDCD1 PROTEIN, HUMAN;

B LYMPHOCYTE; DNA POLYMORPHISM; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE FUNCTION; NONHUMAN; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY;

ANIMALS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 85020067267     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.05.025     Document Type: Review

References (74)

1. Firestein, G.S., Evolving concepts of rheumatoid arthritis. Nature 423:6937 (2003), 356–361.
2. Lopez-Mejias, R., Castaneda, S., Gonzalez-Juanatey, C., et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: the relevance of clinical, genetic and serological markers. Autoimmun Rev 15:11 (2016), 1013–1030.
3. Klareskog, L., van der Heijde, D., de Jager, J.P., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:9410 (2004), 675–681.
4. Lipsky, P.E., van der Heijde, D.M., St Clair, E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343:22 (2000), 1594–1602.
5. Weinblatt, M.E., Keystone, E.C., Furst, D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:1 (2003), 35–45.
6. Smolen, J., Landewe, R.B., Mease, P., et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68:6 (2009), 797–804.
7. Keystone, E.C., Genovese, M.C., Klareskog, L., et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 68:6 (2009), 789–796.
8. Imamura, F., Aono, H., Hasunuma, T., et al. Monoclonal expansion of synoviocytes in rheumatoid arthritis. Arthritis Rheum 41:11 (1998), 1979–1986.
9. Waase, I., Kayser, C., Carlson, P.J., Goronzy, J.J., Weyand, C.M., Oligoclonal T cell proliferation in patients with rheumatoid arthritis and their unaffected siblings. Arthritis Rheum 39:6 (1996), 904–913.
10. Firestein, G.S., Echeverri, F., Yeo, M., Zvaifler, N.J., Green, D.R., Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 94:20 (1997), 10895–10900.
11. Reme, T., Travaglio, A., Gueydon, E., Adla, L., Jorgensen, C., Sany, J., Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue. Clin Exp Immunol 111:2 (1998), 353–358.
12. Inazuka, M., Tahira, T., Horiuchi, T., et al. Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology (Oxford) 39:3 (2000), 262–266.
13. van der Helm-van Mil, A.H., Wesoly, J.Z., Huizinga, T.W., Understanding the genetic contribution to rheumatoid arthritis. Curr Opin Rheumatol 17:3 (2005), 299–304.
14. Okada, Y., Wu, D., Trynka, G., et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506:7488 (2014), 376–381.
15. Gregersen, P.K., Silver, J., Winchester, R.J., The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:11 (1987), 1205–1213.
16. Ye, H., Zhang, J., Wang, J., et al. CD4 T-cell transcriptome analysis reveals aberrant regulation of STAT3 and Wnt signaling pathways in rheumatoid arthritis: evidence from a case-control study. Arthritis Res Ther, 17, 2015, 76.
17. Brand, D.D., Latham, K.A., Rosloniec, E.F., Collagen-induced arthritis. Nat Protoc 2:5 (2007), 1269–1275.
18. Mauri, C., Chu, C.Q., Woodrow, D., Mori, L., Londei, M., Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody. J Immunol 159:10 (1997), 5032–5041.
19. Sakaguchi, N., Takahashi, T., Hata, H., et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426:6965 (2003), 454–460.
20. Weyand, C.M., Goronzy, J.J., Ectopic germinal center formation in rheumatoid synovitis. Ann N Y Acad Sci 987 (2003), 140–149.
21. Bugatti, S., Manzo, A., Bombardieri, M., et al. Synovial tissue heterogeneity and peripheral blood biomarkers. Curr Rheumatol Rep 13:5 (2011), 440–448.
22. Cunha, B.M., Mota, L.M., Pileggi, G.S., Safe, I.P., Lacerda, M.V., HIV/AIDS and rheumatoid arthritis. Autoimmun Rev 14:5 (2015), 396–400.
23. Caporali, R., Bugatti, S., Cavagna, L., Antivalle, M., Sarzi-Puttini, P., Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?. Autoimmun Rev 13:1 (2014), 49–53.
24. Genovese, M.C., Becker, J.C., Schiff, M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:11 (2005), 1114–1123.
25. Westhovens, R., Robles, M., Ximenes, A.C., et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68:12 (2009), 1870–1877.
26. Kremer, J.M., Genant, H.K., Moreland, L.W., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144:12 (2006), 865–876.
27. Yun, H., Xie, F., Delzell, E., et al. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis 74:6 (2015), 1065–1071.
28. Agata, Y., Kawasaki, A., Nishimura, H., et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:5 (1996), 765–772.
29. Thibult, M.L., Mamessier, E., Gertner-Dardenne, J., et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol 25:2 (2013), 129–137.
30. Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., Honjo, T., PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 98:24 (2001), 13866–13871.
31. Goodman, A., Patel, S.P., Kurzrock, R., PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol, 2016.
32. Ansell, S.M., Lesokhin, A.M., Borrello, I., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:4 (2015), 311–319.
33. DeFranco, A.L., Germinal centers and autoimmune disease in humans and mice. Immunol Cell Biol 94:10 (2016), 918–924.
34. Corsiero, E., Nerviani, A., Bombardieri, M., Pitzalis, C., Ectopic lymphoid structures: powerhouse of autoimmunity. Front Immunol, 7, 2016, 430.
35. Pedoeem, A., Azoulay-Alfaguter, I., Strazza, M., Silverman, G.J., Mor, A., Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 153:1 (2014), 145–152.
36. Bretscher, P., Cohn, M., A theory of self-nonself discrimination. Science 169:3950 (1970), 1042–1049.
37. Chen, L., Flies, D.B., Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13:4 (2013), 227–242.
38. − T cells in patients with rheumatoid arthritis. Arthritis Res Ther 5:4 (2003), R210–R213.
39. + T cell exhaustion during chronic viral infection. Immunity 27:4 (2007), 670–684.
40. Jiang, Y., Li, Y., Zhu, B., T-cell exhaustion in the tumor microenvironment. Cell Death Dis, 6, 2015, e1792.
41. Weber, J.S., Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book, 2012, 174–177.
42. Nishimura, H., Nose, M., Hiai, H., Minato, N., Honjo, T., Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:2 (1999), 141–151.
43. Nishimura, H., Okazaki, T., Tanaka, Y., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:5502 (2001), 319–322.
44. Wang, G., Hu, P., Yang, J., Shen, G., Wu, X., The effects of PDL-Ig on collagen-induced arthritis. Rheumatol Int 31:4 (2011), 513–519.
45. Raptopoulou, A.P., Bertsias, G., Makrygiannakis, D., et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum 62:7 (2010), 1870–1880.
46. Prokunina, L., Padyukov, L., Bennet, A., et al. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 50:6 (2004), 1770–1773.
47. Lin, S.C., Yen, J.H., Tsai, J.J., et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 50:3 (2004), 770–775.
48. Liu, C., Jiang, J., Gao, L., et al. A promoter region polymorphism in PDCD-1 gene is associated with risk of rheumatoid arthritis in the Han Chinese population of Southeastern China. Int J Genomics, 2014, 2014, 247637.
49. Tahoori, M.T., Pourfathollah, A.A., Akhlaghi, M., Daneshmandi, S., Nicknam, M.H., Soleimanifar, N., Association of programmed cell death-1 (PDCD-1) gene polymorphisms with rheumatoid arthritis in Iranian patients. Clin Exp Rheumatol 29:5 (2011), 763–767.
50. Prokunina, L., Gunnarsson, I., Sturfelt, G., et al. The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum 50:1 (2004), 327–328.
51. Mori, M., Yamada, R., Kobayashi, K., Kawaida, R., Yamamoto, K., Ethnic differences in allele frequency of autoimmune-disease-associated SNPs. J Hum Genet 50:5 (2005), 264–266.
52. Wang, S.C., Lin, C.H., Ou, T.T., et al. Ligands for programmed cell death 1 gene in patients with systemic lupus erythematosus. J Rheumatol 34:4 (2007), 721–725.
53. Wang, S.C., Lin, C.H., Li, R.N., et al. Polymorphisms of genes for programmed cell death 1 ligands in patients with rheumatoid arthritis. J Clin Immunol 27:6 (2007), 563–567.
54. + T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol 30:7 (2003), 1410–1419.
55. + T cells in rheumatoid arthritis. Inflammation 37:1 (2014), 116–121.
56. Greisen, S.R., Rasmussen, T.K., Stengaard-Pedersen, K., et al. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand J Rheumatol 43:2 (2014), 101–108.
57. Rao, D.A., Gurish, M.F., Marshall, J.L., et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 542:7639 (2017), 110–114.
58. Liu, Y., Shu, Q., Gao, L., et al. Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity. Clin Immunol 137:2 (2010), 288–295.
59. Begovich, A.B., Carlton, V.E., Honigberg, L.A., et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75:2 (2004), 330–337.
60. Vang, T., Congia, M., Macis, M.D., et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 37:12 (2005), 1317–1319.
61. Watford, W.T., Hissong, B.D., Bream, J.H., Kanno, Y., Muul, L., O'Shea, J.J., Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 202 (2004), 139–156.
62. Plenge, R.M., Seielstad, M., Padyukov, L., et al. TRAF1-C5 as a risk locus for rheumatoid arthritis—a genomewide study. N Engl J Med 357:12 (2007), 1199–1209.
63. Liang, Y.L., Wu, H., Shen, X., et al. Association of STAT4 rs7574865 polymorphism with autoimmune diseases: a meta-analysis. Mol Biol Rep 39:9 (2012), 8873–8882.
64. Raychaudhuri, S., Remmers, E.F., Lee, A.T., et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 40:10 (2008), 1216–1223.
65. Nepom, G.T., Byers, P., Seyfried, C., et al. HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum 32:1 (1989), 15–21.
66. Wordsworth, B.P., Lanchbury, J.S., Sakkas, L.I., Welsh, K.I., Panayi, G.S., Bell, J.I., HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A 86:24 (1989), 10049–10053.
67. Fries, J.F., Wolfe, F., Apple, R., et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum 46:9 (2002), 2320–2329.
68. Kochi, Y., Okada, Y., Suzuki, A., et al. A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 42:6 (2010), 515–519.
69. Cheng, P., Zhang, Y., Huang, H., et al. Association between CCR6 and rheumatoid arthritis: a meta-analysis. Int J Clin Exp Med 8:4 (2015), 5388–5396.
70. Iwamoto, T., Ikari, K., Nakamura, T., et al. Association between PADI4 and rheumatoid arthritis: a meta-analysis. Rheumatology (Oxford) 45:7 (2006), 804–807.
71. Chang, X., Yamada, R., Suzuki, A., et al. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 44:1 (2005), 40–50.
72. Orozco, G., Eyre, S., Hinks, A., et al. Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. Ann Rheum Dis 69:5 (2010), 813–816.
73. Kurreeman, F.A., Daha, N.A., Chang, M., et al. Association of IL2RA and IL2RB with rheumatoid arthritis: a replication study in a Dutch population. Ann Rheum Dis 68:11 (2009), 1789–1790.
74. Raychaudhuri, S., Thomson, B.P., Remmers, E.F., et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 41:12 (2009), 1313–1318.